1100 WINTER STREET, WALTHAM, MA
Reports Second Quarter 2026 Financial Results and Provides Business Updates
CFO Appointment - Liisa Bayko Named Chief Financial Officer
Investor Presentation
Director Resignation and Election at Kalaris Therapeutics
Kalaris Therapeutics Elects New Class III Directors at Annual Meeting
Reports First Quarter 2026 Financial Results and Provides Business Updates
Annual Report to Security Holders
CFO Resignation - Matthew Gall Steps Down at Kalaris Therapeutics
Q2
Q1
Q3
FY 2024
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
SEC Staff Correspondence
Correspondence
Submission Upload